Table 10.

Efficacy results of phase 3 IMbrave150 study: OS and PFS [modified from 47]

Co-primary endpoints	Atezo + Beva (n = 336)	Sorafenib (n = 165)
OS
Median, months	NE	13.2 (10.4 to NE)
Hazard ratio	0.58 (0.42–0.79)
p value	0.0006
PFS
Median, months	6.8 (5.7–8.3)	4.3 (4.0–5.6)
Hazard ratio	0.59 (0.47–0.76)
p value	<0.0001

Median duration of follow-up: 8.6 months. Figures in parentheses are 95% CI. OS, overall survival; PFS, progression-free survival; Atezo, atezolizumab; Beva, bevacizumab; NE, not estimable.